JP2021527053A5 - - Google Patents

Info

Publication number
JP2021527053A5
JP2021527053A5 JP2020567857A JP2020567857A JP2021527053A5 JP 2021527053 A5 JP2021527053 A5 JP 2021527053A5 JP 2020567857 A JP2020567857 A JP 2020567857A JP 2020567857 A JP2020567857 A JP 2020567857A JP 2021527053 A5 JP2021527053 A5 JP 2021527053A5
Authority
JP
Japan
Prior art keywords
amino
pharmaceutically acceptable
carboxylic acid
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020567857A
Other languages
English (en)
Japanese (ja)
Other versions
JP7387179B2 (ja
JP2021527053A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/035934 external-priority patent/WO2019236938A1/en
Publication of JP2021527053A publication Critical patent/JP2021527053A/ja
Publication of JP2021527053A5 publication Critical patent/JP2021527053A5/ja
Application granted granted Critical
Publication of JP7387179B2 publication Critical patent/JP7387179B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020567857A 2018-06-07 2019-06-07 発達障害の処置における(s)-3-アミノ-4-(ジフルオロメチレニル)シクロペンタ-1-エン-1-カルボン酸および関連化合物、(1s,3s)-3-アミノ-4-(ジフルオロメチリデン)シクロペンタン-1-カルボン酸ならびにビガバトリンの使用 Active JP7387179B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862681913P 2018-06-07 2018-06-07
US62/681,913 2018-06-07
PCT/US2019/035934 WO2019236938A1 (en) 2018-06-07 2019-06-07 Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders

Publications (3)

Publication Number Publication Date
JP2021527053A JP2021527053A (ja) 2021-10-11
JP2021527053A5 true JP2021527053A5 (cg-RX-API-DMAC10.html) 2022-06-14
JP7387179B2 JP7387179B2 (ja) 2023-11-28

Family

ID=68765508

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020567857A Active JP7387179B2 (ja) 2018-06-07 2019-06-07 発達障害の処置における(s)-3-アミノ-4-(ジフルオロメチレニル)シクロペンタ-1-エン-1-カルボン酸および関連化合物、(1s,3s)-3-アミノ-4-(ジフルオロメチリデン)シクロペンタン-1-カルボン酸ならびにビガバトリンの使用

Country Status (12)

Country Link
US (3) US10813899B2 (cg-RX-API-DMAC10.html)
EP (1) EP3813816B1 (cg-RX-API-DMAC10.html)
JP (1) JP7387179B2 (cg-RX-API-DMAC10.html)
KR (1) KR102744830B1 (cg-RX-API-DMAC10.html)
CN (1) CN112770739B (cg-RX-API-DMAC10.html)
AU (1) AU2019280980B2 (cg-RX-API-DMAC10.html)
CA (1) CA3102786A1 (cg-RX-API-DMAC10.html)
ES (1) ES2948263T3 (cg-RX-API-DMAC10.html)
IL (2) IL279220B2 (cg-RX-API-DMAC10.html)
MX (2) MX2020013290A (cg-RX-API-DMAC10.html)
PL (1) PL3813816T3 (cg-RX-API-DMAC10.html)
WO (1) WO2019236938A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019236938A1 (en) 2018-06-07 2019-12-12 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
WO2020039262A1 (en) 2018-08-18 2020-02-27 Ftf Pharma Private Limited Pharmaceuticals solution for oral dosage
WO2024058812A1 (en) 2022-09-16 2024-03-21 Pyros Pharmaceuticals, Inc. Vigabatrin liquid pharmaceutical composition
IL322802A (en) 2023-02-17 2025-10-01 Ovid Therapeutics Inc Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of gastrointestinal disorders and as an immunomodulatory agent
US20240285565A1 (en) 2023-02-17 2024-08-29 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of diabetes and pre-diabetes
US20260130878A1 (en) * 2024-11-12 2026-05-14 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of pain

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794413B1 (en) 2002-07-19 2004-09-21 Northwestern University Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase
WO2005120496A2 (en) 2004-05-24 2005-12-22 Regents Of The University Of California TREATING LEARNING DEFICITS WITH INHIBITORS OF HMG CoA REDUCTASE
WO2009033818A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
CA2790820A1 (en) 2010-02-25 2011-09-01 Northwestern University Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor
US20130230586A1 (en) 2010-10-02 2013-09-05 Link Research & Grants Corporation Treatment of Tinnitus and Related Auditory Dysfunctions
WO2013006857A1 (en) 2011-07-07 2013-01-10 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism
WO2013112363A1 (en) 2012-01-27 2013-08-01 Catalyst Pharmaceutical Partners Method of treating tourette's disorder with gaba-aminotransferase inactivators
TW201606304A (zh) * 2013-09-09 2016-02-16 亞克柏拉有限公司 測定治療反應之方法
US20150224164A1 (en) 2013-11-26 2015-08-13 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid
AU2015342801A1 (en) 2014-11-07 2017-05-18 Hadasit Medical Research Services And Development Ltd. Ornithine aminotransferase inhibition with GABA Analogues for treatment of hepatocellular carcinoma
US20170348232A1 (en) * 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
CN108137484B (zh) * 2015-10-09 2021-02-12 西北大学 作为用于治疗癫痫、成瘾和肝细胞癌的gaba氨基转移酶灭活剂的化合物
US10632088B2 (en) 2016-10-10 2020-04-28 Northwestern University Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria
KR20240110989A (ko) * 2017-02-08 2024-07-16 오비드 테라퓨틱스 인크. 프라더-윌리 증후군 및 발작 장애들을 치료하는 방법들
US20200268711A1 (en) * 2017-11-14 2020-08-27 Sk Biopharmaceuticals Co., Ltd. Use Of Carbamate Compound For Reducing Or Treating Developmental Disorders Including Fragile X Syndrome, Angelman Syndrome Or Rett Syndrome
JP7475055B2 (ja) 2018-05-25 2024-04-26 ノースウェスタン ユニバーシティ (s)-3-アミノ-4-(ジフルオロメチレニル)シクロペンタ-1-エン-1-カルボン酸の合成法
WO2019236938A1 (en) 2018-06-07 2019-12-12 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders

Similar Documents

Publication Publication Date Title
CA2470956A1 (en) 1-alkyl-1-azoniabicyclo[2.2.2]octane carbamate derivatives and their use as muscarinic receptor antagonists
JP2024517738A5 (cg-RX-API-DMAC10.html)
CL2012001056A1 (es) Compuestos derivados de cromenona sustituidos, inhibidores de enzimas pi 3 quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion de trastornos de proliferacion celular, tales como tumores enfermedades inflamatorias y fibroticas, asma, diabetes insulinodependiente, entre otras.
CA2894417A1 (en) Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
JP2015522630A5 (cg-RX-API-DMAC10.html)
JP2023537921A5 (cg-RX-API-DMAC10.html)
JP2007520452A5 (cg-RX-API-DMAC10.html)
WO2000068229A3 (en) (s)-benzoquinolizine carboxylic acids and their use as antibacterial agents
US20220296553A1 (en) Compositions for treating fungal and bacterial biofilms and methods of using the same
AR050463A1 (es) Analagos de lonidamina y su uso en anticoncepcion masculina y en el tratamiento contra el cancer.
IL292770A (en) Formulations and dosages of polyethylene glycol-modified oricase
WO2023081482A9 (en) Combination of a bile acid and a phenyl butyrate compound for the treatment of neurodegenerative diseases
MX2020013290A (es) Uso del acido (s)-3-amino-4-(difluorometilenil) ciclopent-1-eno-1-carboxilico y compuestos relacionados, acido (1s,3s)-3-amino-4-(difluorometilideno) ciclopentano-1-carboxilico y vigabatrina en el tratamiento de trastornos del desarrollo.
CN104955447A (zh) 用于减轻口干燥症状和用于治疗口溃疡的局部口腔组合物
JP2013523628A5 (cg-RX-API-DMAC10.html)
BRPI0411702A (pt) uso de ácido hialurÈnico para preparar composições para o tratamento de aftas da cavidade oral
JP2022028975A5 (cg-RX-API-DMAC10.html)
JP2022503733A5 (cg-RX-API-DMAC10.html)
JP2020536098A5 (cg-RX-API-DMAC10.html)
MX2023001572A (es) Formas farmaceuticas sólidas de palbociclib.
JP2020527138A5 (cg-RX-API-DMAC10.html)
MX2025012741A (es) Composiciones farmaceuticas orales
RU2014151156A (ru) Налмефен для уменьшения потребления алкоголя у конкретных целевых популяций
JP2018531961A5 (cg-RX-API-DMAC10.html)